1 cells, graft cellular composition, and post-transplant hematologic recovery in 26 patients with multiple myeloma after lenalidomide-based induction and in 34 lenalidomidenaive controls with multiple myeloma. All patients were mobilized with low-dose cyclophosphamide plus granulocyte-colony-stimulating factor. The cellular composition of the grafts was analyzed from thawed, cryopreserved samples with flow cytometry. Graft function was evaluated by engraftment data and by complete blood counts until 12 months after the graft infusion.
RESULTS:
Patients in the lenalidomide arm had lower median peak CD34 1 counts and approximately 40% lower CD34 1 cell yields from the first apheresis session, but these differences were not significant. The median total number of CD34 1 cells collected was comparable a positive impact on response rate, progression-free survival (PFS), and overall survival. 1, 2 The introduction of novel agents, such as proteasome inhibitors and immunomodulatory drugs, as induction therapy has yielded higher response rates as well as better outcomes. 3 Richardson and coworkers 4 reported that a combination of lenalidomide (LEN), bortezomib, and dexamethasone (RVD) was a highly effective regimen in previously untreated patients with myeloma. In a more recent study, a French group concluded that an ASCT-based approach with three cycles of RVD as induction therapy was successful without engraftment delay or unexpected complications. 5 A recent
Southwest Oncology Group study 6 compared RVD with a combination of LEN and dexamethasone (RD) in a randomized Phase 3 study and concluded that RVD is the current standard of care in the first-line setting. A large randomized study (IFM 2009) comparing ASCT after RVD versus a nontransplant approach was recently published. 7 More recently, three drug regimens, including carfilzomib, LEN, and dexamethasone 8 or a completely oral combination of ixazomib, LEN, and dexamethasone, 9 have been evaluated as initial therapy in MM. The best induction therapy in the front-line setting is currently unknown, as is the ideal method for CD34 1 cell mobilization to maximize cell yields with reasonable efforts and costs. [10] [11] [12] Successful peripheral blood stem cell mobilization remains a key factor for ASCT. The potential impact of initial therapy on the peripheral blood stem cell collection process has been evaluated. 13 In two retrospective studies, initial therapy with LEN had an adverse impact on the ability to collect stem cells. 14, 15 In a Finnish prospective, randomized trial, cyclophosphamide-based mobilization was more effective after RVD induction compared with granulocyte-colony-stimulating factor (G-CSF) mobilization alone; however, in both arms, the minimal collection target was reached in all patients with similar need for plerixafor use. 16 No prospectively collected data are available on graft composition regarding CD34 1 subclasses and lymphocyte subsets or on post-transplant hematologic recovery in patients who are treated with LEN before mobilization and the collection of blood grafts.
The objective of the current prospective, multicenter study was to evaluate the mobilization of CD34 1 cells, blood graft cellular composition, and post-transplant hematologic recovery in patients with MM after LENbased induction compared with LEN-naive patients with MM. All patients were mobilized with low-dose cyclophosphamide (LD-CY) plus G-CSF. 16 In addition, one patient switched to a bortezomib and dexamethasone regimen after the first cycle of RVD because of toxicity, another was treated with RVD outside the MM-02 protocol, and one received RD as first-line therapy. Eight additional patients were treated with LEN 25mg on Days 1 through 21 together with dexamethasone as a second-line option after bortezomib and dexamethasone/bortezomib, dexamethasone, and cyclophosphamide induction to improve treatment response before stem cell mobilization and ASCT. The median number of LEN courses was three. The control group LEN(2) consisted of 34 patients who had not received LEN before mobilization and autograft collection. The characteristics of these patient groups are presented in Table 1 .
PATIENTS AND METHODS

Patients and LEN treatment
Mobilization and collection of blood grafts
All patients received chemomobilization, which consisted of LD-CY (2 g/m 2 ) on Day 1 combined with G-CSF. Blood CD34 1 (B-CD34 1 ) counts were monitored daily from Day 10 until completion of apheresis by flow cytometry.
Apheresis was started when a sufficient B-CD34
/L) was reached and was continued for consecutive days if needed. In patients who were participating in the prospective MM-02 study, the predetermined collection target was at least 3 3 10 6 /kg CD34 1 cells for a single transplant and at least 6 3 10 6 /kg for patients who had an option for two transplants. The minimum collection target to proceed to ASCT was at least 2 3 10 6 /kg of CD34 1 cells in all study centers. One patient (4%) in the LEN(1) group and two patients (6%) in the control group required plerixafor (p 5 0.720). Apheresis was performed using the Spectra Optia MNC Program at Kuopio, Oulu, and Tampere University Hospitals (Spectra Optia, version 7.2.; Terumo BCT). At Turku University Hospital, apheresis was performed using Fresenius COM.TEC (Fresenius Hemo Care GmbH). The daily blood volume circulated was from 2.3 to 3 times the estimated total blood volume of the given patient. CD34 1 counts in the apheresis products were measured after every session by flow cytometry using an International Society for Hematotherapy and Graft Engineering (ISHAGE) protocol with a single-platform method in the stem cell laboratory at each apheresis center. 17 
Graft analysis
After each apheresis session, two extra 0.5-mL specimens were taken for later analyses from the apheresis products and processed in the same way as the grafts. Dimethyl sulfoxide was added to the products (final concentration, 10%) to protect the cells from stress or death caused by cryopreservation. The final products were frozen in a liquid nitrogen freezer with a controlled-rate freezing program. Graft samples from three other stem cell laboratories at the university laboratories in Oulu, Turku, and Tampere were transported overnight in dry ice (at 2788C) to the Department of Clinical Microbiology, University of Eastern Finland, for the analysis of graft cellular composition. 
Statistical analysis
Analyses were performed within all patients and between the two arms. Numeric continuous variables were described using medians with ranges, and categorical variables were expressed in percentages. Comparisons of continuous variables between the two cohorts were performed using the Mann-Whitney U-test and the Fisher exact test to compare categorical variables between the study groups. All statistical tests were performed with statistical software (SPSS Statistics version 23; IBM Corporation). Two-tailored p values less than 0.05 were considered significant. 
RESULTS
Mobilization efficiency and collection of blood grafts
All patients who were included in this study achieved the minimum collection target of at least 2 3 10 6 /kg CD34 1 cells ( Table 2 ). The median number of CD34 
Graft composition
Data regarding cellular composition of the grafts after thawing are presented in Table 3 . The numbers of CD34 (2) arm (p 5 0.152). There were no early (<100 days) treatment-related deaths. Hematologic recovery (hemoglobin, white blood cells, neutrophils, lymphocytes, and platelets) was comparable between the groups during the first 12 months after ASCT at Day 15 and at 1, 3, 6, and 12 months. 
Post-transplant outcome
Fifty-three patients (88%) were alive at the time of the analysis (September 1, 2016). Ten patients (38%) in the LEN(1) arm and 22 (64%) in the control arm have experienced a relapse or disease progression. Kaplan-Meier curves for the groups are shown in Figure 1 and demonstrate significantly better PFS in the LEN(1) group (p 5 0.027). Figure 2 shows PFS in the LEN(1) group according to LEN maintenance (n 5 14) compared with no maintenance (n 5 12; p 5 0.207).
DISCUSSION
This prospective, multicenter study is a part of the GOA study. The objectives of the GOA study were to evaluate sufficient numbers of patients with MM and nonHodgkin's lymphoma, the relation between the mobilization methods used, the graft cellular composition, as well as post-transplant recovery and patient outcomes. This study included all patients with MM who were recruited into the GOA study before the end of 2014 and were mobilized with LD-CY plus G-CSF. The main conclusion of the study was that limited LEN exposure before CY-based mobilization resulted in somewhat inferior mobilization of CD34 1 cells, although adequate grafts to perform a single ASCT could be collected in all patients. Furthermore, the graft composition was comparable to that in patients without prior LEN exposure. The graft quality did not appear to be compromised by LEN use, as reflected in the comparable engraftment kinetics and equal hematologic recovery within 12 months post-transplant. These observations are of importance with regard to the increasingly more common use of LEN also in transplant-eligible patients before the mobilization of CD34 1 cells. 16 concluded that, even if CY-based mobilization was more effective, G-CSF alone also was successful in stem cell mobilization after three cycles of LEN-based induction with a need for plerixafor in only 14% of patients. The European Group for Blood and Marrow Transplantation expert panel has suggested risk factors for impaired stem cell mobilization, including advanced disease stage, older age, previous irradiation, prolonged chemotherapy, and type of chemotherapy. 10, 19 The CD34 1 cell count in peripheral blood before apheresis is the most powerful predictive factor for a successful collection. 19 Li and coworkers 20 concluded that LEN is not toxic to hematopoietic stem cells; however, by inducing increased C-X-C chemokine receptor type 4 surface expression and promoting the stromal cell-derived factor 1a-induced migration of CD34 1 cells, the block of mobilization of CD34 1 cells may happen. Pal and colleagues 21 suggested that LEN down regulates the key transcription factor (PU.1) involved in granulocyte differentiation, resulting in a transient maturation arrest of immature myeloid precursors and subsequent neutropenia. In our study, which included only patients who had limited LEN exposure, somewhat inferior mobilization was observed in the LEN(1) group; but it is interesting to note that there was no increase in the incidence of poor mobilizers (B-CD34 1 maximum <20 3 10 6 /L). Our prospective, multicenter study also showed that, after a median of three LEN courses, the minimum collection targets can be reached in practically all patients who receive LD-CY plus G-CSF, although there seems to be a need for more aphereses in LEN-exposed patients.
As far as we are aware, no previous studies have compared graft cellular composition between LEN-exposed and LEN-naive patients. We observed comparable numbers of both CD34
1 cells and primitive CD34 1 CD133 1 CD38 2 cells in the grafts. There were greater numbers of T lymphocytes and NK cells in the grafts from the LEN group, but the difference was not significant. The function of the grafts was not impaired by LEN exposure, as reflected by the equal tempo of engraftment as well as comparable hematologic recovery within 12 months post-transplant. Also, some earlier observations suggest equal engraftment kinetics in LEN-exposed patients. 14, 22, 23 PFS was significantly better in the LEN(1) group, although the groups were small, and only 53% of patients in the LEN(1) group received LEN maintenance as a part of the Phase 2 study. A recent study suggested that posttransplant maintenance was more important than the type of induction regimen used in patients with MM. 24 In our study, patients who received LEN-based induction and LEN maintenance did not have significantly better PFS compared with those who did not receive maintenance, although the groups were very small. Our observations corroborate the findings to date from at least three placebo-controlled, randomized studies that have demonstrated an advantage of LEN maintenance after ASCT. [25] [26] [27] An obvious limitation of our study is the quite small patient numbers, although we included all eligible patients within the study period from four university hospitals. In addition, the cumulative dose of LEN was limited but was in line with its current use as an induction regimen of three or four cycles. However, this prospective multicenter study also has strengths, including the initial setting of the study, the identical mobilization regimen for all included patients, and the fact that all graft analyses were performed centrally by the same experienced flow cytometrist.
In conclusion, limited exposure to LEN had some effect on the mobilization capacity of CD34 1 cells, although adequate grafts could be obtained from the great majority of the patients who received LD-CY plus G-CSF. The collected grafts had good quality, as indicated by rapid and stable engraftment in all patients. Thus, LEN might be used as a part of first-line induction regimen also in transplant-eligible patients. Our observations do not directly apply to patients with prolonged exposure to LEN before mobilization of CD34 1 cells. These patients may have more difficulties in the mobilization of adequate blood grafts and may benefit from pre-emptive plerixafor use. [28] [29] [30] CONFLICT 
